Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Common Equity: 2017-2025

Historic Common Equity for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Sep 2025 value amounting to $1.1 billion.

  • Crinetics Pharmaceuticals' Common Equity rose 28.71% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 28.71%. This contributed to the annual value of $1.3 billion for FY2024, which is 145.74% up from last year.
  • Crinetics Pharmaceuticals' Common Equity amounted to $1.1 billion in Q3 2025, which was down 8.48% from $1.2 billion recorded in Q2 2025.
  • Crinetics Pharmaceuticals' Common Equity's 5-year high stood at $1.3 billion during Q4 2024, with a 5-year trough of $149.5 million in Q1 2021.
  • For the 3-year period, Crinetics Pharmaceuticals' Common Equity averaged around $816.6 million, with its median value being $833.0 million (2024).
  • Per our database at Business Quant, Crinetics Pharmaceuticals' Common Equity slumped by 34.19% in 2023 and then skyrocketed by 226.92% in 2024.
  • Quarterly analysis of 5 years shows Crinetics Pharmaceuticals' Common Equity stood at $331.9 million in 2021, then dropped by 4.70% to $316.3 million in 2022, then soared by 70.43% to $539.1 million in 2023, then surged by 145.74% to $1.3 billion in 2024, then increased by 28.71% to $1.1 billion in 2025.
  • Its last three reported values are $1.1 billion in Q3 2025, $1.2 billion for Q2 2025, and $1.3 billion during Q1 2025.